Trials / Unknown
UnknownNCT00152685
High Dose Hyperoncotic Serum Albumin for the Treatment of the Acute Phase of Severe Head Injury
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- University Hospital, Angers · Other Government
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Experimentally high dose of hyperoncotic human serum albumin improve neurological recovery after head injury reduce cerebral edema and normalize apparent diffusion coefficient of water after ischemia reperfusion. The main hypothesis is that early administration of hyperoncotic serum albumin is able to reduce intracranial pressure for several days after severe head injury and thus reduce mortality and morbidity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | human serum albumin |
Timeline
- First posted
- 2005-09-09
- Last updated
- 2005-12-01
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT00152685. Inclusion in this directory is not an endorsement.